The concomitant expression of HOXA9 and WNT6 results in overactivation of the WNT/β‐catenin signaling pathway in vitro and in vivo, and identifies a subgroup of glioblastoma patients with particularly dismal prognosis, suggesting this HOXA9‐WNT6 link may be an attractive therapeutic target. Here, HOXA9 is linked to glioblastoma.